NICE may recommend Erbitux in metastatic colorectal cancer after all
This article was originally published in Scrip
Executive Summary
Colorectal cancer patients in the national health service in England and Wales may be given access to Merck Serono's (Merck KGaA) Erbitux (cetuximab) in narrow circumstances, new draft guidance from the National Institute for health and Clinical Excellence (NICE) suggests.